The hematopoietic toxicity of regional radiation therapy. Correlations for combined modality therapy with systemic chemotherapy

R. A. Abrams, A. S. Lichter, R. H. Bromer, J. D. Minna, M. H. Cohen, A. B. Deisseroth

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Using circulating granulocyte-monocyte precursor colony-forming units in culture (CFUc) numbers as a probe along with standard blood count (CBC), the authors have quantitatively examined the hematopoietic toxicity of conventionally fractionated radiation therapy (RT) when combined with concurrent systemic chemotherapy or when used alone. Among 20 patients with limited stage small cell lung cancer receiving systemic chemotherapy with cyclophosphamide, CCNU, and methotrexate, the addition of involved field chest RT resulted in increased hematopoietic toxicity as judged by increased need for platelet transfusion (P < 0.05) and decreased frequency of measurable CFUc (P < 0.04). Among 22 patients receiving regional radiotherapy alone consistent hematopoietic toxicity was also observed. This toxicity, although generally of only mild to moderate clinical significance, was detected earlier and to a greater degree in patients who required radiation to larger treatment volumes, who had significant amounts of bone marrow in the port, and who had a high percentage of cardiac output flowing through the port. These data suggest that the hematopoietic toxicity of regional radiotherapy may be additive to that of concurrent systemic chemotherapy and may occur more promptly and to a greater degree when treatment volumes are larger or incorporate increased amounts of marrow volume or cardiac output.

Original languageEnglish (US)
Pages (from-to)1429-1435
Number of pages7
JournalCancer
Volume55
Issue number7
DOIs
StatePublished - 1985

Fingerprint

Combined Modality Therapy
Radiotherapy
Drug Therapy
Stem Cells
Bone Marrow
High Cardiac Output
Lomustine
Platelet Transfusion
Small Cell Lung Carcinoma
Granulocytes
Methotrexate
Cardiac Output
Cyclophosphamide
Monocytes
Thorax
Radiation
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The hematopoietic toxicity of regional radiation therapy. Correlations for combined modality therapy with systemic chemotherapy. / Abrams, R. A.; Lichter, A. S.; Bromer, R. H.; Minna, J. D.; Cohen, M. H.; Deisseroth, A. B.

In: Cancer, Vol. 55, No. 7, 1985, p. 1429-1435.

Research output: Contribution to journalArticle

Abrams, R. A. ; Lichter, A. S. ; Bromer, R. H. ; Minna, J. D. ; Cohen, M. H. ; Deisseroth, A. B. / The hematopoietic toxicity of regional radiation therapy. Correlations for combined modality therapy with systemic chemotherapy. In: Cancer. 1985 ; Vol. 55, No. 7. pp. 1429-1435.
@article{c60f4db2e770473db514da537072c5dc,
title = "The hematopoietic toxicity of regional radiation therapy. Correlations for combined modality therapy with systemic chemotherapy",
abstract = "Using circulating granulocyte-monocyte precursor colony-forming units in culture (CFUc) numbers as a probe along with standard blood count (CBC), the authors have quantitatively examined the hematopoietic toxicity of conventionally fractionated radiation therapy (RT) when combined with concurrent systemic chemotherapy or when used alone. Among 20 patients with limited stage small cell lung cancer receiving systemic chemotherapy with cyclophosphamide, CCNU, and methotrexate, the addition of involved field chest RT resulted in increased hematopoietic toxicity as judged by increased need for platelet transfusion (P < 0.05) and decreased frequency of measurable CFUc (P < 0.04). Among 22 patients receiving regional radiotherapy alone consistent hematopoietic toxicity was also observed. This toxicity, although generally of only mild to moderate clinical significance, was detected earlier and to a greater degree in patients who required radiation to larger treatment volumes, who had significant amounts of bone marrow in the port, and who had a high percentage of cardiac output flowing through the port. These data suggest that the hematopoietic toxicity of regional radiotherapy may be additive to that of concurrent systemic chemotherapy and may occur more promptly and to a greater degree when treatment volumes are larger or incorporate increased amounts of marrow volume or cardiac output.",
author = "Abrams, {R. A.} and Lichter, {A. S.} and Bromer, {R. H.} and Minna, {J. D.} and Cohen, {M. H.} and Deisseroth, {A. B.}",
year = "1985",
doi = "10.1002/1097-0142(19850401)55:7<1429::AID-CNCR2820550702>3.0.CO;2-4",
language = "English (US)",
volume = "55",
pages = "1429--1435",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - The hematopoietic toxicity of regional radiation therapy. Correlations for combined modality therapy with systemic chemotherapy

AU - Abrams, R. A.

AU - Lichter, A. S.

AU - Bromer, R. H.

AU - Minna, J. D.

AU - Cohen, M. H.

AU - Deisseroth, A. B.

PY - 1985

Y1 - 1985

N2 - Using circulating granulocyte-monocyte precursor colony-forming units in culture (CFUc) numbers as a probe along with standard blood count (CBC), the authors have quantitatively examined the hematopoietic toxicity of conventionally fractionated radiation therapy (RT) when combined with concurrent systemic chemotherapy or when used alone. Among 20 patients with limited stage small cell lung cancer receiving systemic chemotherapy with cyclophosphamide, CCNU, and methotrexate, the addition of involved field chest RT resulted in increased hematopoietic toxicity as judged by increased need for platelet transfusion (P < 0.05) and decreased frequency of measurable CFUc (P < 0.04). Among 22 patients receiving regional radiotherapy alone consistent hematopoietic toxicity was also observed. This toxicity, although generally of only mild to moderate clinical significance, was detected earlier and to a greater degree in patients who required radiation to larger treatment volumes, who had significant amounts of bone marrow in the port, and who had a high percentage of cardiac output flowing through the port. These data suggest that the hematopoietic toxicity of regional radiotherapy may be additive to that of concurrent systemic chemotherapy and may occur more promptly and to a greater degree when treatment volumes are larger or incorporate increased amounts of marrow volume or cardiac output.

AB - Using circulating granulocyte-monocyte precursor colony-forming units in culture (CFUc) numbers as a probe along with standard blood count (CBC), the authors have quantitatively examined the hematopoietic toxicity of conventionally fractionated radiation therapy (RT) when combined with concurrent systemic chemotherapy or when used alone. Among 20 patients with limited stage small cell lung cancer receiving systemic chemotherapy with cyclophosphamide, CCNU, and methotrexate, the addition of involved field chest RT resulted in increased hematopoietic toxicity as judged by increased need for platelet transfusion (P < 0.05) and decreased frequency of measurable CFUc (P < 0.04). Among 22 patients receiving regional radiotherapy alone consistent hematopoietic toxicity was also observed. This toxicity, although generally of only mild to moderate clinical significance, was detected earlier and to a greater degree in patients who required radiation to larger treatment volumes, who had significant amounts of bone marrow in the port, and who had a high percentage of cardiac output flowing through the port. These data suggest that the hematopoietic toxicity of regional radiotherapy may be additive to that of concurrent systemic chemotherapy and may occur more promptly and to a greater degree when treatment volumes are larger or incorporate increased amounts of marrow volume or cardiac output.

UR - http://www.scopus.com/inward/record.url?scp=0021921993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021921993&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19850401)55:7<1429::AID-CNCR2820550702>3.0.CO;2-4

DO - 10.1002/1097-0142(19850401)55:7<1429::AID-CNCR2820550702>3.0.CO;2-4

M3 - Article

C2 - 2983854

AN - SCOPUS:0021921993

VL - 55

SP - 1429

EP - 1435

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -